Growth-hormone-derived peptide studied for effects on fat metabolism
Clinical research
Read the profile Peptide profile
Tirzepatide
GIP and GLP-1 receptor agonist
Approved medicines exist
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
Mounjaro is an FDA-approved tirzepatide product for type 2 diabetes. Product approvals do not establish the safety or approval of compounded versions.
View the supporting source- Research area
- Metabolic
- Biological target or mechanism
- GIP and GLP-1 receptor agonist
- Evidence context
- Approved medicines exist
- Availability
- Availability requires pharmacy review
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
